Skip to main content
OpenTrials

Clinical trial condition

Focal Segmental Glomerulosclerosis

Explore clinical trials studying Focal Segmental Glomerulosclerosis. Study availability and eligibility vary by location and protocol.

42 public trials 16 recruiting studies
Refine in advanced search Browse all conditions

Focal Segmental Glomerulosclerosis trial results

Completed

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337

Conditions
Abnormalities, Multiple, Autoimmune Diseases, Autosomal Dominant Polycystic Kidney, +21 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • Phoenician Centers for Research & Innovation (PCRI) Phoenix, Arizona, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Denver Nephrology Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +9 more
Locations
  • Balboa Nephrology Medical Group San Diego, California, United States
  • Los Angeles Biomedical Research Institute Torrance, California, United States
  • Colorado Kidney Care Denver, Colorado, United States
  • University of Miami Miller School of Medicine Miami, Florida, United States
View all 33 locations
View Trial Details
Completed

A Study of CCX140-B in Subjects With FSGS

NCT03536754

Conditions
FSGS, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • AKDHC Phoenix, Arizona, United States
  • Los Angeles Biomedical Research Institute Torrance, California, United States
  • Northwest Louisiana Nephrology Shreveport, Louisiana, United States
  • MGH Boston, Massachusetts, United States
View all 37 locations
View Trial Details
Completed

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668

Conditions
FSGS, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
Locations
  • The University of Michigan Ann Arbor, Michigan, United States
  • New York University New York, United States
  • Levine Children's Hospital/Atrium Health Charlotte, North Carolina, United States
  • Cleveland Clinic Foundation Cleveland, Ohio, United States
View Trial Details
Completed

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • Travere Investigational Site San Francisco, California, United States
  • Travere Investigational Site Belmar, New Jersey, United States
  • Travere Investigational Site Chapel Hill, North Carolina, United States
  • Travere Investigational Site King of Prussia, Pennsylvania, United States
View Trial Details
Completed

LDL-Apheresis for FSGS CardioRenal Outcomes

NCT04088799

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
  • Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States
View Trial Details
Completed

Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan

NCT03649152

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • Renal Research Gosford, New South Wales, Australia
  • Liverpool Hospital Liverpool, New South Wales, Australia
  • Royal North Shore Hospital St Leonards, New South Wales, Australia
  • Westmead Westmead, New South Wales, Australia
View Trial Details
Completed

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +11 more
Locations
  • The University Of Alabama At Birmingham Birmingham, Alabama, United States
  • University of Alabama-Birmingham-Parent Account Birmingham, Alabama, United States
  • Los Angeles Biomedical Research Institute Torrance, California, United States
  • University Of Colorado Denver Aurora, Colorado, United States
View all 27 locations
View Trial Details

Related conditions